New diagnostic options such as dihydroxyphenylalanine (DOPA)-positron emission tomography and, the more recent, GLP-1 scintigraphy, could have been useful to confirm the localization of the suspected insulinoma. The gene discussed is GLP1R; the disease is pancreatic insulinoma.